{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:01:24Z","timestamp":1790841684391,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejim.2026.107052","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T11:47:36Z","timestamp":1782733656000},"page":"107052","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Testosterone therapy in chronic kidney disease patients: an underutilized resource"],"prefix":"10.1016","volume":"152","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7113-2372","authenticated-orcid":false,"given":"Sandro","family":"La Vignera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosita A.","family":"Condorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejim.2026.107052_bib0001","doi-asserted-by":"crossref","DOI":"10.5527\/wjn.v15.i1.113875","article-title":"Endocrine disorders linked to chronic kidney disease: mechanisms and clinical implications","volume":"15","author":"Concepci\u00f3n-Zavaleta","year":"2026","journal-title":"World J Nephrol"},{"issue":"11","key":"10.1016\/j.ejim.2026.107052_bib0002","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1093\/ndt\/gfs383","article-title":"The vulnerable man: impact of testosterone deficiency on the uraemic phenotype","volume":"27","author":"Carrero","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1016\/j.ejim.2026.107052_bib0003","first-page":"548","article-title":"Role of testosterone in the pathogenesis, progression, prognosis and comorbidity of men with chronic kidney disease","volume":"17","author":"Dousdampanis","year":"2013","journal-title":"Ther Apher Dial"},{"issue":"1","key":"10.1016\/j.ejim.2026.107052_bib0004","doi-asserted-by":"crossref","first-page":"31","DOI":"10.5301\/JN.2011.8481","article-title":"Gonadal dysfunction in men with chronic kidney disease: clinical features, prognostic implications and therapeutic options","volume":"25","author":"Iglesias","year":"2012","journal-title":"J Nephrol"},{"issue":"2","key":"10.1016\/j.ejim.2026.107052_bib0005","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1053\/j.ajkd.2013.06.010","article-title":"Serum testosterone levels and clinical outcomes in male hemodialysis patients","volume":"63","author":"Bello","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1016\/j.ejim.2026.107052_bib0006","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.ajkd.2014.03.010","article-title":"Serum testosterone levels and mortality in men with CKD stages 3-4","volume":"64","author":"Khurana","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"16","key":"10.1016\/j.ejim.2026.107052_bib0007","doi-asserted-by":"crossref","DOI":"10.3390\/nu14163444","article-title":"Testosterone replacement therapy in chronic kidney disease patients","volume":"14","author":"Skiba","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.ejim.2026.107052_bib0008","article-title":"Testosterone deficiency and chronic kidney disease","volume":"37","author":"Zitzmann","year":"2024","journal-title":"J Clin Transl Endocrinol"},{"key":"10.1016\/j.ejim.2026.107052_bib0009","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2026.1744953","article-title":"Male hypogonadism in patients on maintenance hemodiafiltration: prevalence and therapeutic effect","volume":"17","author":"Carvalho","year":"2026","journal-title":"Front Endocrinol"},{"issue":"5","key":"10.1016\/j.ejim.2026.107052_bib0010","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.22394","article-title":"The association between serum testosterone and mortality among elderly men on hemodialysis","volume":"32","author":"Wu","year":"2018","journal-title":"J Clin Lab Anal"},{"issue":"9","key":"10.1016\/j.ejim.2026.107052_bib0011","first-page":"820","article-title":"A randomized controlled trial of testosterone undecanoate for improving quality of sex life of the male continuous hemodialysis patients","volume":"3","author":"Pan","year":"2010","journal-title":"Chin. J. New Clin. Med."},{"issue":"3","key":"10.1016\/j.ejim.2026.107052_bib0012","doi-asserted-by":"crossref","DOI":"10.1177\/1557988320917258","article-title":"Effects of testosterone treatment on quality of life in patients with chronic kidney disease","volume":"14","author":"Yeo","year":"2020","journal-title":"Am J Men Health"},{"issue":"4","key":"10.1016\/j.ejim.2026.107052_bib0013","first-page":"556","article-title":"A case series of the safety and efficacy of testosterone replacement therapy in renal failure and kidney transplant patients","volume":"5","author":"Majzoub","year":"2016","journal-title":"Transl Androl Urol"},{"issue":"1","key":"10.1016\/j.ejim.2026.107052_bib0014","article-title":"Long-term testosterone treatment improves fatty liver and kidney function with safe outcomes on cardio-, metabolic and prostate health in men with hypogonadism. Prospective controlled studies","volume":"6","author":"Yassin","year":"2022","journal-title":"Curr Trends Intern Med"},{"issue":"Supplement 1","key":"10.1016\/j.ejim.2026.107052_bib0015","article-title":"409-P: long-term testosterone treatment improves estimated glomerular filtration rate (eGFR) in men with hypogonadism and type 2 diabetes mellitus: update of registry data","volume":"71","author":"Haider","year":"2022","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.ejim.2026.107052_bib0016","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12933-025-02930-2","article-title":"Testosterone therapy is associated with reduced risk of acute kidney injury, kidney failure with renal replacement therapy, and cardiovascular events in men with diabetes and hypogonadism","volume":"24","author":"Bonnet","year":"2025","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"10.1016\/j.ejim.2026.107052_bib0017","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa2215025","article-title":"Cardiovascular safety of testosterone-replacement therapy","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"Suppl_1","key":"10.1016\/j.ejim.2026.107052_bib0018","doi-asserted-by":"crossref","DOI":"10.1161\/circ.150.suppl_1.4142355","article-title":"Abstract 4142355: effect of testosterone replacement therapy on cardiovascular outcomes in males: a meta-analysis of randomized controlled trials","volume":"150","author":"Paul","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2026.107052_bib0019","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3389\/fphys.2012.00089","article-title":"Testosterone and vascular function in aging","volume":"3","author":"Lopes","year":"2012","journal-title":"Front Physiol"},{"issue":"1","key":"10.1016\/j.ejim.2026.107052_bib0020","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s12265-019-09939-5","article-title":"Vascular pathways of testosterone: clinical implications","volume":"13","author":"Lorigo","year":"2020","journal-title":"J Cardiovasc Transl Res"},{"issue":"13","key":"10.1016\/j.ejim.2026.107052_bib0021","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1042\/CS20170090","article-title":"Genomic and non-genomic effects of androgens in the cardiovascular system: clinical implications","volume":"131","author":"Lucas-Herald","year":"2017","journal-title":"Clin Sci"},{"issue":"3","key":"10.1016\/j.ejim.2026.107052_bib0022","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/aja.2012.21","article-title":"Testosterone and cardiovascular disease in men","volume":"14","author":"Morris","year":"2012","journal-title":"Asian J Androl"},{"issue":"7","key":"10.1016\/j.ejim.2026.107052_bib0023","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.2215\/CJN.10681210","article-title":"Endogenous testosterone, endothelial dysfunction, and cardiovascular events in men with nondialysis chronic kidney disease","volume":"6","author":"Yilmaz","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.ejim.2026.107052_bib0024","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-015284","article-title":"Testosterone therapy in hypogonadal men: a systematic review and network meta-analysis","volume":"7","author":"Elliott","year":"2017","journal-title":"BMJ Open"},{"issue":"10","key":"10.1016\/j.ejim.2026.107052_bib0025","first-page":"3469","article-title":"Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men","volume":"84","author":"Dobs","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.ejim.2026.107052_bib0026","doi-asserted-by":"crossref","first-page":"5429","DOI":"10.1210\/jc.2004-0897","article-title":"Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism","volume":"89","author":"Schubert","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ejim.2026.107052_bib0027","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/13685538.2022.2063830","article-title":"The HEAT-registry (hematopoietic affection by testosterone): comparison of a transdermal gel vs long-acting intramuscular testosterone undecanoate in hypogonadal men","volume":"25","author":"Zitzmann","year":"2022","journal-title":"Aging Male"},{"issue":"6","key":"10.1016\/j.ejim.2026.107052_bib0028","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1046\/j.1365-2265.1997.3071113.x","article-title":"Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men","volume":"47","author":"Arver","year":"1997","journal-title":"Clin Endocrinol"},{"issue":"12","key":"10.1016\/j.ejim.2026.107052_bib0029","first-page":"4500","article-title":"Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men","volume":"85","author":"Swerdloff","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ejim.2026.107052_bib0030","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1310\/hct0806-412","article-title":"Prospective study of topical testosterone gel (AndroGel) versus intramuscular testosterone in testosterone-deficient HIV-infected men","volume":"8","author":"Scott","year":"2007","journal-title":"HIV Clin Trials"},{"issue":"3","key":"10.1016\/j.ejim.2026.107052_bib0031","article-title":"Efficacy and safety of testosterone replacement gel for treating hypogonadism in men: phase III open-label studies","volume":"50","author":"Belkoff","year":"2018","journal-title":"Andrologia"},{"key":"10.1016\/j.ejim.2026.107052_bib0032","article-title":"The impact of long-term testosterone therapy (TTh) in renal function (RF) among hypogonadal men: an observational cohort study","volume":"70","author":"Alwani","year":"2021","journal-title":"Ann Med Surg"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620526003572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620526003572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:42:52Z","timestamp":1790840572000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620526003572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":32,"alternative-id":["S0953620526003572"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2026.107052","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Testosterone therapy in chronic kidney disease patients: an underutilized resource","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2026.107052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}],"article-number":"107052"}}